InvestorsObserver
×
News Home

Should You Add Chromadex Corp (CDXC) Stock to Your Portfolio Monday?

Monday, June 27, 2022 03:31 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Add Chromadex Corp (CDXC) Stock to Your Portfolio Monday?

Chromadex Corp (CDXC) is around the top of the Healthcare sector according to InvestorsObserver. CDXC received an overall rating of 78, which means that it scores higher than 78% of stocks. Additionally, Chromadex Corp scored a 77 in the Healthcare sector, ranking it higher than 77% of stocks in that sector.

Overall Score - 78
CDXC has an Overall Score of 78. Find out what this means to you and get the rest of the rankings on CDXC!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 78 means the stock is more attractive than 78 percent of stocks. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Chromadex Corp Stock Today?

Chromadex Corp (CDXC) stock is trading at $1.87 as of 3:27 PM on Monday, Jun 27, a decline of -$0.05, or -2.86% from the previous closing price of $1.92. The stock has traded between $1.80 and $1.98 so far today. Volume today is light. So far 540,104 shares have traded compared to average volume of 733,202 shares. Click Here to get the full Stock Report for Chromadex Corp stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App